Last reviewed · How we verify

doxazosin plus tolterodine SR

Samsung Medical Center · FDA-approved active Small molecule Quality 2/100

doxazosin plus tolterodine SR is a Small molecule drug developed by Samsung Medical Center. It is currently FDA-approved. Also known as: Cadura XL 4mg or 8mg, Detrusitol SR 2mg.

At a glance

Generic namedoxazosin plus tolterodine SR
Also known asCadura XL 4mg or 8mg, Detrusitol SR 2mg
SponsorSamsung Medical Center
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about doxazosin plus tolterodine SR

What is doxazosin plus tolterodine SR?

doxazosin plus tolterodine SR is a Small molecule drug developed by Samsung Medical Center.

Who makes doxazosin plus tolterodine SR?

doxazosin plus tolterodine SR is developed and marketed by Samsung Medical Center (see full Samsung Medical Center pipeline at /company/samsung-medical-center).

Is doxazosin plus tolterodine SR also known as anything else?

doxazosin plus tolterodine SR is also known as Cadura XL 4mg or 8mg, Detrusitol SR 2mg.

What development phase is doxazosin plus tolterodine SR in?

doxazosin plus tolterodine SR is FDA-approved (marketed).

Related